Silver Book Fact

Fact image

The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately $0.7 trillion, for a 1 year delay in Alzheimer’s disease onset for all new cases from 2010 to 2050 (QUALY valued at $100,000), to almost $4 trillion, for a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 (QUALY valued at $175,000).

Vernon, John, Robert Goldberg, Yashodhara Dash, and Guruprasaadh Muralimohan. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon, John, Robert Goldberg, Yashodhara Dash, and Guruprasaadh Muralimohan
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…  
  • A treatment breakthrough that slowed the progression of Alzheimer’s disease would reduce the number of people with the disease from 2.4 million to 1.1 million in 2020, and from 6.5…  
  • It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…  
  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.